Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

Jingli GuJunru LiuXiaozhe LiWaiyi ZouBeihui HuangMeilan ChenJuan Li

Published in: Cancer medicine (2021)

rhTPO accelerated the platelet engraftment after ASCT in patients with NDMM with good tolerability and long-term safety, especially for those patients with poor CD34+ cell reinfusion. rhTPO might be recommended to be used early after ASCT for patients with NDMM.

Keyphrases

recombinant human
newly diagnosed
multiple myeloma
cell therapy
hematopoietic stem cell
single cell
acute myeloid leukemia
bone marrow
cell free
open label
stem cells
mesenchymal stem cells
clinical trial
nk cells
placebo controlled